Pediatric Asthma Exacerbation in Children with Suspected and Confirmed Coronavirus Disease 2019 (COVID-19): An Observational Study from Saudi Arabia

• Published in: Journal of asthma and allergy Vol. 14; pp. 1139 - 1146
• Main Author: Asseri, Ali Alsuheel
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01-01-2021; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Age; Asthma; asthma exacerbation; Asthma in children; Children; Childrens health; Coronaviruses; Cough; COVID-19; Diagnosis; Disease; Fever; Gene expression; Genotype & phenotype; Health aspects; Hospitalization; Hospitals; Hypoxia; Immunoglobulins; Infection; Infections; Influenza; Laboratories; Leukocytes (eosinophilic); Lung diseases; Mechanical ventilation; Medical research; Medicine, Experimental; Morbidity; Mortality; Nose; Observational studies; Original Research; Outdoor air quality; Pandemics; Patients; Pediatrics; Phenotypes; Polymerase chain reaction; Rhinovirus; sars-cov-2; Severe acute respiratory syndrome coronavirus 2; Statistical analysis; Steroids; Tracheostomy; Viral infections; Saudi Arabia; China; COVID-19; asthma exacerbation; SARS-CoV-2; children
• ISSN: 1178-6965; 1178-6965
• DOI: 10.2147/JAA.S326860

Most asthma exacerbations are caused by viral respiratory infections such as rhinovirus, coronaviruses, influenza viruses, and many others. While there have been data about the impact of COVID-19 on adult asthma, much remains unknown about the impact of COVID-19 on childhood asthma.
This retrospective cohort study included all pediatric patients aged 2 to 12 years who were admitted to Abha Maternity and Children Hospital for acute asthma exacerbation between June 1, 2020, and May 31, 2021, and underwent testing for SARS-CoV-2 using nasopharyngeal real-time polymerase chain reaction.
Sixty children hospitalized with the diagnosis of asthma were included in the study. Out of these patients, 10 (16.7%) were diagnosed with COVID-19. The enrolled patients were between 2 and 12 years, with a median age of five years (interquartile range, 3.8), and 58% were males (35/60). Cough, shortness of breath, and hypoxia were the most common presenting symptoms and signs. Severe asthma was more prevalent among positive COVID-19 compared with negative COVID-19 patients (60 vs 20%; P= 0.016). In addition, chronic asthma for more than five years was more prevalent among positive COVID-19 than negative COVID-19 patients (60 vs 40%, P= 0.305). Fifty-five percent of the enrolled patients had eosinophilic asthma using a 300cells/μL threshold. None of the children required invasive respiratory support (ventilation through an endotracheal tube or tracheostomy), but 12 patients (21.7%) required respiratory support via high-flow nasal cannula. The total days of hospitalization in either PICU or pediatric general ward did not differ between the two groups. All patients were discharged, and there were no reports of serious morbidity or mortality.
Eosinophilic asthma was the most prevalent asthma phenotype in the study group. Furthermore, there was no difference in the presenting symptoms of an asthma flare-up, laboratory indicators, and hospitalization outcomes (critical care admission and hospital stay) between asthmatics with and without a COVID-19 diagnosis.